OrganaBio launches decentralized support division for vaccine and cell and gene therapy clinical trials
OrganaBio launches decentralized support division for vaccine and cell and gene therapy clinical trials
OrganaBio launches decentralized support division for vaccine and cell and gene therapy clinical trials
New plant will supply cell therapy products for late-stage clinical trials and future product launches / Supports clinical studies with BlueRock Therapeutics’ investigational cell therapy for Parkinson’s Disease bemdaneprocel (BRT-DA01) / New facility located in Berkeley, California, USA
PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.
Artificial Intelligence (AI) has proven to be a game-changer for life science recruitment, opening up access to a wide range of tools designed to streamline and enhance the hiring process.
IRVINE, Calif., Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women's trajectories through college and career entry. The Allergan Aesthetics effort will focus specifically on leadership paths in STEM (science, technology, engineering, and math).
In today’s competitive job market, traditional hiring methods often struggle to keep pace with the evolving needs of the life science industry. Faced with an ever-increasing talent shortage, now is the time to explore new approaches to talent acquisition that will help to expand your talent pool, streamline your recruitment process, and improve employee engagement and retention.
As a major and expansive sector, the life science industry wields immense influence over the global environment. With its wide range of products and services encompassing pharmaceuticals, medical devices, biotechnology and more, the industry’s activities can have a profound impact on both human health and the planet at large.
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.
AI-powered tools for CV screening are quickly becoming a go-to solution for talent acquisition professionals in the life science industry. In this article, we explore 10 AI-powered tools designed for CV screening. By leveraging these tools, you’ll be able to streamline your recruitment process, focus your time on the best candidates, and ultimately make better hiring decisions for your organisation.
Castres, France and Cambridge UK, 25 September 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.